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Abstract
Fibroblast growth factor receptor 4 (FGFR-4) is expressed at significant levels in almost all human prostate cancers,
and expression of its ligands is ubiquitous. A common polymorphism of FGFR-4 in which arginine (Arg388) replaces
glycine (Gly388) at amino acid 388 is associated with progression in human prostate cancer. We show that the
FGFR-4 Arg388 polymorphism, which is present in most prostate cancer patients, results in increased receptor
stability and sustained receptor activation. In patients bearing the FGFR-4 Gly388 variant, expression of Huntingtin-
interacting protein 1 (HIP1), which occurs in more than half of human prostate cancers, also results in FGFR-4 sta-
bilization. This is associated with enhanced proliferation and anchorage-independent growth in vitro. Our findings
indicate that increased receptor stability and sustained FGFR-4 signaling occur in most human prostate cancers
due to either the presence of a common genetic polymorphism or the expression of a protein that stabilizes
FGFR-4. Both of these alterations are associated with clinical progression in patients with prostate cancer. Thus,
FGFR-4 signaling and receptor turnover are important potential therapeutic targets in prostate cancer.
Neoplasia (2008) 10, 847–856
Introduction
Prostate cancer is the most common cancer and the second leading
cause of cancer deaths in American men [1]. Multiple genetic and
epigenetic alterations have been described in prostate cancer, which
can promote initiation and progression of this disease. Prominent
among these changes are alterations in the fibroblast growth factor
(FGF) signaling pathway (for review, see Kwabi-Addo et al. [2]).
Fibroblast growth factors have a broad range of biologic activities that
can play an important role in tumorigenesis including promotion of
proliferation, motility, and angiogenesis and inhibition of cell death
[2–5]. It is well established that multiple FGF receptor ligands are
increased in prostate cancer [6–12] and, on the basis of correlations
with clinical and pathologic parameters, seem to play a role in pros-
tate cancer progression. Fibroblast growth factors interact with a
family of four distinct, high-affinity tyrosine kinase receptors, desig-
nated FGFR-1–4 (for review, see Powers et al. [3]). Activation of
FGF receptors leads to signal transduction through multiple path-
ways [2,3,13], and all of these pathways have been shown to be
up-regulated in prostate cancer, and each contributes to prostate can-
cer initiation and progression [2,14].
There is now clear-cut evidence for the involvement of FGFR-4 in
prostate cancer initiation and progression. All of the FGFs that are
increased in human prostate cancer tissues are potent activators of
FGFR-4. Our group [15] and others [16,17] have shown increased
expression of FGFR-4 in prostate cancer by quantitative reverse
transcription–polymerase chain reaction (RT-PCR) and immuno-
histochemistry. Strong expression of FGFR-4 in prostate cancer cells,
as assessed by immunohistochemistry, is significantly associated with
increased clinical stage and tumor grade and decreased patient sur-
vival [16]. On the basis of these studies, it is clear that FGFR-4 is
expressed in almost all human prostate cancers.
A germ line polymorphism in the FGFR-4 gene, resulting in the
expression of FGFR-4 containing either glycine (Gly388) or arginine
(Arg388) at codon 388 was identified several years ago, and the presence
of the FGFR-4 Arg388 allele was associated with decreased disease-free
survival in breast cancer patients with lymph node metastasis as well as
with metastasis and poor prognosis in colon cancer [18]. Since the initial
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report, further studies in a variety of malignancies, including soft tissue
sarcomas [19], melanoma [20], lung adenocarcinoma [21], and head
and neck squamous cell carcinoma [22,23] have linked the presence
of the FGFR-4 Arg388 allele with aggressive disease and adverse clinical
outcomes. There have been some discordant reports regarding the role
of the FGFR-4 Arg388 in breast cancer [24], but this may be explained
by differences in treatment regimen, because recent studies indicate that
the FGFR-4 Arg388 polymorphism modulates response to chemother-
apy [25]. We have found that the presence of homozygosity for the
FGFR-4 Arg388 allele is significantly associated with prostate cancer in-
cidence in white men [15]. Furthermore, the presence of the FGFR-4
Arg388 polymorphism is correlated with the occurrence of pelvic lymph
node metastasis and biochemical (PSA) recurrence in men undergoing
radical prostatectomy [15]. Expression of the FGFR-4 Arg388 variant
results in increased cell motility and invasion as well as up-regulation
of genes such as uPAR [15] and Ehm2 [26], which are known to pro-
mote invasion and metastasis. These in vitro observations may explain,
in part, the increased aggressiveness of prostate cancer in men bearing
this polymorphism. This polymorphism is very prevalent in the white
population, because approximately 45% of individuals are hetero- or
homozygous for this allele in all white populations studied to date.
Although the expression of the FGFR-4 Arg388 variant is associated
with prostate cancer initiation and aggressive disease, an important
question remains: what is the molecular basis for the difference be-
tween the two FGFR-4 variants? Achondroplasia is caused by a similar
mutation in FGFR-3 (Gly380 to Arg380). Increased FGFR-3 signaling
due to this mutation inhibits proliferation in chondrocytes [27,28] and
hence the phenotype. Elegant studies have shown that this mutation
leads to decreased receptor turnover due to increased receptor recycling
and decreased targeting of receptors to lysosomes [27,28]. We there-
fore sought to determine whether a similar phenomenon occurs with
the FGFR-4 Arg388 variant. In addition, we have begun to investigate
other proteins that can potentially modulate FGFR-4 receptor stability.
One such protein is Huntingtin-interacting protein 1 (HIP1). It can
interact with clathrin as well α-adaptin, which is part of the AP-2 late
endocytic complex [29]. It has been shown that HIP1 can stabilize
epidermal growth factor (EGF) receptors [29,30], and the primary site
of such stabilization seems to be through stabilization in early endo-
somes [29]. Overexpression of HIP1 leads to transformation of
NIH3T3 cells [30]. Of note, it has been shown using immunohisto-
chemistry that there is a moderate to strong expression of HIP1 in
approximately 50% of clinically localized prostate cancers and that
absence of HIP1 expression is associated with complete absence of bio-
chemical recurrence after radical prostatectomy [31]. We report here
that the FGFR-4 Arg388 variant has markedly decreased degradation
and increased phosphorylation after ligand binding when compared
to the Gly388 variant. Conversely, the interaction with HIP1 stabilizes
the FGFR-4 Gly388 variant and results in increased proliferation and
soft agar colony formation. Thus, altered FGFR-4 receptor trafficking
is a common feature in human prostate cancer, which is associated
with changes in cellular behavior in vitro and clinical progression.
Materials and Methods
Tissue Samples and Cell Lines
RNA were extracted from snap-frozen cancer tissues (>70% can-
cer) and benign peripheral zone tissue from men undergoing radical
prostatectomy as described previously [32]. PNT1A, a nontumori-
genic SV40-immortalized human prostatic epithelial cell line, and
the PC3, LNCaP, and DU145 prostate cancer cell lines were all
maintained in RPMI 1640 medium with 10% fetal bovine serum
(FBS). 293T cells were maintained in DMEM with 10% FBS.
Sh-FGFR-4 and Sh-HIP1 Lentivirus
Lentiviruses to knock down FGFR-4 or HIP1 RNA were generated
using Block-iT Lentiviral RNAi Expression System (Invitrogen, Carlsbad,
CA). Primers used for lentiviral constructs were as follows: Sh R4 F
5′CACCGCATAGGGACCTCTCGAAT ATTCGAAAATATTC-
GAGAGGTCCCTATGC-3′, Sh R4 R 5′AAAAGCATAGG-
GACCTCTC GAATATTTTCGAATA TTCGAGAGGTCCCT
ATGC-3′, Sh-HIP1F 5′- CACCGGACTCAGACT GTCAGCAT-
CACGAATGATGCTGACAGTCTGAGTCC -3′, Sh-HIP1R 5′-
AAAAGGACTCAGAC TGTCAGCATCATTCGTGATGCTGA-
CAGTCTGAGTCC -3′. Lentiviral constructs were generated according
to the manufacturer’s instruction using 293FT cells. After infection
with lentivirus, cells were selected in blasticidin (2 μg/ml)–containing
medium. RNA was extracted from pooled cells, and mRNA levels of
target genes were quantitated by quantitative RT-PCR.
Expression Vector Cloning, Transfection, and Stable Selection
The full-length FGFR-4 Gly388 and Arg388 isoforms were obtained
from DU145 and PC3 cell line cDNA, respectively, and cloned into
Topo-V5 expression vector (Invitrogen) by using primers of FGFR-4
Exp F: 5′- CCT GAGAGCTGTGAGAAG G-3′; and FGFR-4 Exp
R: 5′-GGATCCAGCTCCTTCCCC-3′. Annealing temperature was
60°C. HIP1 constructs were cloned into pCMV-Tag2B expression
vector (Stratagene, La Jolla, CA), which has a Flag Tag at N terminal
in frame. The full-length HIP1 and N-terminal truncated HIP1(−183)
sequences were obtained from PNT1A cell line cDNA by RT-PCR
using primers with a 5′ SalI cutting site and a 3′ XhoI site. Primers
were as follows: HIP1 Exp F (SalI): 5′- ACGCGTCGACATGGAT-
CGGAT G-3′; HIP1 Exp F2 (SalI): 5′-ACGCGTCGACCAGTTAA
CAGTGGAG -3′; HIP1 Exp R (XhoI): 5′-CCGCTCGAGTTCTT-
TTTCGGTTACCA C-3′. All constructs were sequenced to confirm
the absence of mutations due to the PCR reaction and verify the ac-
curacy of the tag sequences in frame. The expression of full-length pro-
teins was confirmed by Western blot using cell lysate from transiently
transfected 293T cells overexpressing FGFR-4 or HIP1. Anti-V5 anti-
body (1:5000) from Invitrogen and anti-Flag antibody (1:2000) from
Stratagene were used. To generate stable cell lines, 3 × 105 cells per
60-mm dish were prepared 24 hours before transfection. Approximately
2 μg of plasmid was transfected with 6 μl of Fugene6 (Invitrogen) in a
total volume of 4 ml of OPTI-MEM without serum. Five hours after
transfection, 1 ml of FBS was then added to each dish to achieve a
final serum concentration of 20%. After an additional 18 hours of in-
cubation, cells were refed with complete medium and then split 1:3
after 48 hours. The next day, selection was initiated by the addition
of G418 at 200 μg/ml. Selection was carried out for 2 weeks, and
long-term cultures were routinely maintained in G418 (100 μg/ml).
Generation of PNT1A Cells Stably Expressing FGFR-4
Gly388 and Arg 388
FGFR-4 Gly388 variant (GI 33873872) transcript was amplified
and cloned into pCR2.1-Topo (Invitrogen) using primers GTTC-
TAGAGCCATGCGGCTGCTGCTGGCCCTGTTGGG and
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CGGGCCCGC TGTCTGCACCCCAGACCCGAAGGGG. The
FGFR-4 encoding fragment was released by XbaI/ApaI and sub-
cloned into pcDNA 3.1/V5-His-Topo vector (Invitrogen) to create
a V5-tagged FGFR-4 expression cassette. The V5-tagged FGFR-4
Arg388 variant was obtained by site-directed mutagenesis of the above
construct using primers CCTGGCCTTGGCTGTGCTCCTGCTG
CTGGCCAGGCTGTATCG and GCCGTGGAGCGCCTGCCC-
TCGATACAGCCTGGCCAGCAGCAG (codon 388 from GGG to
AGG). The above V5-tagged FGFR-4 protein-encoding cassettes were
released by XbaI/PmeI digestion and inserted into a lentiviral vector
pCDH-MCS1-EF1-Puro (SBI, Mountain View, CA) digested by
XbaI/SwaI to create pCDH-FGFR4(Gly388)-EF1-Puro and pCDH-
FGFR4(Arg388)-EF1-Puro. By cotransfection of pCDH-FGFR4
(Gly388)-EF1-Puro and pCDH-FGFR4(Arg388)-EF1-Puro with the
necessary packaging plasmids in 293 cells, lentiviruses were generated
to transduce PNT1A cells. After transduction, PNT1A cells express-
ing FGFR-4 Gly388 and Arg388 were stably selected in puromycin-
containing medium.
Western Blot and Immunoprecipitation
Total protein was extracted from cells using RIPA lysis buffer (Santa
Cruz Biotechnology, Santa Cruz, CA). For Western blots, 40 μg of
protein extract/lane were electrophoresed, transferred to nitrocellulose
membrane (Hybond ECL; Amersham Biosciences, Piscataway, NJ),
and incubated overnight with an anti-V5 monoclonal antibody (at
1:5000 dilution; Invitrogen), anti-Flag M2 monoclonal antibody (at
1:2000 dilution; Stratagene), anti–FGFR-4 (at 1:500 dilution; Santa
Cruz Biotechnology), anti-HIP1 (at 1:10,000 dilution; Novus Biolog-
icals, Littleton, CO), or anti–β-actin (at 1:5000 dilution; Sigma, St
Louis, MO). Membranes were washed and treated with mouse anti-
goat IgG (at 1:5000 dilution; Santa Cruz Biotechnology) or goat anti-
rabbit (at 1:50,000 dilution; Santa Cruz Biotechnology) conjugated to
horseradish peroxidase. The antigen–antibody reaction was visualized
using an enhanced chemiluminescence (ECL) assay (Amersham Bio-
sciences) and was exposed to ECL film (Amersham Biosciences). For
immunoprecipitation, 1 mg of protein lysate from each sample was
incubated with anti-V5 (1:500) overnight at 4°C. Tyrosine phos-
phorylation of FGFR-4 Tyr641/642 was detected using phospho-FGF
receptor-specific mouse monoclonal antibody (Cell Signaling Tech-
nology, Danvers, MA) at 1:1000 dilution.
Quantitative Real-Time PCR
Quantitative RT-PCR was carried out using the basic procedure
described previously [32]. Primers for HIP1 (GenBank Accession
No. NM_005338). HIP1 RT Forward: 5′-TGCTCTGCTGGAA-
GTTCTG-3′; HIP1 RT Reverse: 5′-CTGGCGGTCACTCAT
CTG -3′. Primers for β-actin were as described previously [32]. All
real-time PCR efficiencies were controlled in the range of 100 ± 5%.
Receptor Degradation Assay
293 cells, 2 × 106, were plated into each 10-cm dishes 24 hours
before transfection. Cells were transfected with 8 μg of plasmid in
total in each dish. At 48 hours after transfection, cells were trypsi-
nized and washed three times with ice-cold PBS. Cell pellets were re-
suspended in PBS at ∼2.5 × 107/ ml. A total of 200 μl of 10 mM
biotin was added into each 1-ml PBS cell suspension. After 15 min-
utes of incubation at 4°C, cells were washed three times using PBS
with 100 mM glycine. They were then replated at 37°C with com-
plete DMEM plus 100 ng/ml FGF2 and 20 U/ml heparin for dif-
ferent periods. Cells were collected at 0, 6, 24, and 48 hours and
were lysed with 1 ml of RIPA buffer with 1% Triton and then son-
icated. For immunoprecipitation, 60 μl of streptavidin–agarose beads
were used for 1-mg lysate of each sample, with overnight incuba-
tion at 4°C.
In Vitro Binding Assay
To investigate which domain of HIP1 protein associates with
FGFR-4, we made a series of purified HIP1 proteins with trun-
cated domains by using Variflex Bacterial Protein Expression System
(Stratagene). We used N-terminal SBP-SET2c for HIP1 proteins ex-
pression due to different enzyme cutting sites. Primers used were as
follows: HIP1 Exp F V (SmaI): 5′-TCC CCC GGG ATG GAT
CGG ATG-3′; HIP1 Exp F2 V (SmaI): 5′-TCC CCC GGG
CAG TTA ACA GTG G -3′; HIP1 Exp F3 V (SmaI): 5′-TCC
CCC GGG GAG ATC AGT GGA TTG-3′; HIP1 Exp F4 V
(SmaI): 5′-TCC CCCGGG ACTCAGCTCAAA C-3′; HIP1 Exp
F5 V (SmaI): 5′- TCC CCCGGGGCCAGA ATAGAG-3′; HIP1
Exp R V (XhoI): 5′-CCGCTCGAGCTATTCTTTTTC GGTTAC-
CAC-3′. Purified proteins, dissolved in streptavidin-binding buffer at
0.2 μg/μl, were verified by electrophoresis and Coomassie Blue stain-
ing before being applied to the binding assay. The 293T cell lysate
(350 μl) in RIPA buffer from cells with transient overexpression of
FGFR-4 was mixed with 50 μl of different purified HIP1 domain
proteins. After incubation at 4°C overnight, streptavidin beads were
spun down and washed three times with phosphate-buffered saline/
0.5% Tween 20 followed by standard Western Blot by using anti-
V5 antibody.
Proliferation Assays
PNT1A or DU145 cells overexpressing HIP1 protein or vector con-
trols were plated at 1 × 105 per 60-mmdish. Cells were grown in RPMI
1640 with 10% FBS or 0.5% FBS, or 1% insulin–transferrin–selenium
(Sigma) plus 20 ng/ml FGF2, and were counted at 2, 4, 6, and 8 days.
Cell number was determined in triplicate using a Coulter counter.
Soft Agar Colony Formation Assay
35 mm dishes with 0.5% base agar layer mixed with 1× culture me-
dium plus 10% FBSwere prepared before the seeding of cells. Approx-
imately 105 PNT1A cells transfected with HIP1 expression vector or
control were plated in 0.35% top agar layer over the base agar. Plates
were stained with crystal violet, and cell colonies were counted after
incubating at 37°C in a humidified incubator for 3 weeks.
Migration Assay
Cells were seeded at 2.5 × 106 in 60-mm diameter culture dishes
in complete medium and analyzed using a classic scratch wound
method as described previously [15].
Results
The FGFR-4 Arg 388 Variant Has Decreased Degradation and
Sustained Phosphorylation after Ligand Stimulation
Compared to the Gly388 Variant
To assess differences in receptor degradation between the two
FGFR-4 variants after ligand stimulation, we transfected 293T cells
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with either the Arg388 or Gly388 FGFR-4 variant, biotinylated cell
surface receptors, and lysed cells at intervals after ligand (FGF2) stim-
ulation. Fibroblast growth factor 2 is a known ligand of FGFR-4 [33]
and is present at increased levels in prostate cancer [7]. Biotin-labeled
proteins were then precipitated using streptavidin beads, and the
precipitates were used for Western blots with anti-V5 antibody rec-
ognizing a V-5 tag on the transfected FGFR-4 variants. As can be
seen in Figure 1, the FGFR-4 Arg388 variant is much more stable
than the Gly388 variant. We have repeated this experiment multiple
times with essentially identical results. Thus, the FGFR-4 Arg388 var-
iant is degraded much more slowly than the Gly388 variant after li-
gand binding.
To determine whether there were differences in FGFR-4 receptor
phosphorylation between the two variants, we expressed the FGFR-4
Arg388 and Gly388 variants in the immortalized normal prostatic ep-
ithelial cell line PNT1A using a lentivirus engineered to express V5-
tagged FGFR-4. This cell line is heterozygous for the FGFR-4
Arg388/Gly388 locus, and quantitative RT-PCR reveals that both len-
tivirus infected cell lines express approximately 90-fold higher levels
of FGFR-4 than control PNT1A cells (data not shown). Thus, while
some native FGFR-4 Arg388 is present in the Gly388 overexpressing
cell line, it constitutes approximately 1% of total FGFR-4 in that cell
line and similar considerations hold for the Arg388-overexpressing cell
line. We have shown previously that PNT1A cells expressing the
FGFR-4 Arg388 variant have significantly increased motility when
compared to cells expressing the FGFR-4 Gly388 variant. To confirm
this finding and verify that the V5-tag does not alter the biologic ac-
tivity of FGFR-4, we carried out a scratch assay using the two cell
lines. As seen in Figure 2A, cells expressing the FGFR-4 Arg388 var-
iant migrated and filled the wound much more quickly than cells
expressing the Gly388 variant, consistent with our prior results. We
stimulated cells with FGF2 after overnight incubation in medium
without FGFs. Cells were harvested at intervals and FGFR-4 receptor
phosphorylation assessed using an FGF receptor phosphorylation–
specific antibody after immunoprecipitation with anti-V5 antibody.
This antibody specifically recognizes a completely conserved tyrosine
phosphorylation site present in all FGF receptors [Tyr653/654 in
FGFR-1; Tyr642/643 in FGFR-4 (NP_998812.1)]. This site is phos-
phorylated in response to ligand binding and is essential for FGF re-
ceptor activity [34]. As can be seen in Figure 2B, there is a sustained
phosphorylation of the FGFR-4 Arg388 variant in comparison to the
Gly388 variant after ligand stimulation. Thus, the FGFR-4 Arg388
variant displays increased stability and much higher levels of sus-
tained activation than the Gly388 variant.
HIP1 mRNA Is Increased in Prostate Cancer and
Increased Expression Is Associated with PSA Recurrence
after Radical Prostatectomy
Previous immunohistochemical studies have shown that HIP1 pro-
tein is increased in prostate cancer and that absence of HIP1 staining
was associated with a favorable prognosis after radical prostatectomy
[31]. To confirm these findings using an alternative approach, we
Figure 1. Increased stability of the FGFR-4 Arg388 variant after li-
gand stimulation. 293T cells were transfected with V5-tagged
FGFR-4 Arg388 or Gly388 and cell surface receptors labeled with bio-
tin. Cells were then stimulated with FGF2 and lysed at the indi-
cated time. Labeled receptors were then immunoprecipitated
with streptavidin–agarose and FGFR-4 detected by Western blot
of the immunoprecipitates with anti-V5 antibody. Western blot of
an aliquot of the lysate used for immunoprecipitation with anti–β-
actin antibody is shown.
Figure 2. Sustained phosphorylation of the FGFR-4 Arg388 variant
after ligand stimulation. (A) PNT1A cells expressing V5-tagged
FGFR-4 Arg388 or Gly388 were seeded at 2.5 × 106 in 60-mm diam-
eter culture dishes in complete medium. Cells were gently scraped
with a plastic tip. Themediumwas removed, and cellswerewashed
twice with PBS. Complete medium was added, and cells were al-
lowed to scatter/migrate into the area of clearing for a total of
40 hours, and photomicrographs were taken at 0-, 24-, and 40-hour
time points. Scratch assays were performed four times, and repre-
sentative results are shown. (B) PNT1A cells expressing either
V5-tagged FGFR-4Arg388 (AA) or Gly388 (GG)were plated. After over-
night incubation in medium with insulin as the only growth factor,
cells were stimulated with FGF2 and lysates were prepared at the
indicated times. Tagged FGFR-4 was immunoprecipitated with an
anti-V5 antibody, and the phosphorylated receptor was detected
by Western blot of immunoprecipitates with anti–phospho-FGF-R
antibody (Tyr641/642). Western blot with anti-V5 antibody is shown
to confirm equivalent immunoprecipitation.
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used quantitative RT-PCR to evaluate HIP1 mRNA expression in
normal peripheral zone tissue and cancer tissue from men with no
PSA recurrence within 5 years after radical prostatectomy versus men
with PSA recurrence within 5 years of radical prostatectomy (Figure 3).
We found that HIP1 mRNA is significantly increased in prostate
cancer (P = .018, Mann-Whitney test) and is higher in cancers with
biochemical recurrence after radical prostatectomy versus those with
no recurrence (P = .05; Mann-Whitney rank sum test). Thus, in agree-
ment with prior studies, our results indicate that HIP1 may play an
important role in promoting prostate cancer aggressiveness.
HIP1 Stabilizes FGFR-4 and Promotes Sustained Activation
after Ligand Stimulation
It has been shown previously that HIP1 can increase receptor sta-
bility of EGF receptors. To determine the biochemical and biologic
effects of HIP1 on FGF signaling and FGFR-4, we established cells
lines from the immortalized normal prostate cell line PNT1A and
LNCaP prostate cancer cells expressing HIP1 under a constitutive
promoter. As can be seen in Figure 4A, for both types of cells, expres-
sion of HIP1 in a clone was associated with markedly increased
FGFR-4 protein levels. Quantitative RT-PCR to determine FGFR-
4 receptor mRNA expression levels revealed no increase and, in most
cases, slight decreases in FGFR-4 mRNA levels (Figure 4B). Thus,
HIP1 increases FGFR-4 protein through a posttranscriptional mech-
anism. To determine whether this was due to altered receptor stabil-
ity, we cotransfected 293T cells with either the FGFR-4 variant or
the HIP1 expression constructs. We evaluated receptor stability of
biotin-labeled surface receptors at intervals after ligand stimulation,
followed by precipitation of biotin-labeled proteins from cell lysates
using streptavidin beads, and followed by Western blot analysis with
anti-V5 antibody recognizing a V-5 tag on the transfected FGFR-4
variants. We have found that HIP1 seems to significantly increase the
stability of the FGFR-4 Gly388 variant, while having, at most, minor
effects on FGFR-4 Arg388 stability (Figure 5).
HIP1 Interacts Directly with FGFR-4
We next carried out reciprocal immunoprecipitation Western blot
studies to determine whether there is a direct interaction between the
FGFR-4 variants and HIP1. V5-tagged FGFR-4 and Flag-tagged
HIP1 were cotransfected into 293T cells. Immunoprecipitation with
Figure 3. Quantitation of HIP1 transcripts by quantitative RT-PCR
in prostate cancer. Quantitative RT-PCR was performed on RNA
extracted from benign peripheral zone tissue from radical prosta-
tectomies (PZ) or prostate cancers from patients with no PSA
recurrence within 5 years of surgery (Non-recur) or with PSA recur-
rence (Recur) within 5 years of surgery. β-Actin transcript levels
were used for normalization. Mean ± SD is shown.
Figure 4. Stabilization of FGFR-4 by HIP1 in prostate epithelial and prostate cancer cells. Immortalized normal prostate epithelial cells
(PNT1A) or prostate cancer cells (LNCaP) were transfected with HIP1 in the TOPO-V5 expression vector and stable cells lines selected.
(A) Expression of HIP1 and FGFR-4 protein was evaluated by Western blot with β-actin as a loading control. (B) Expression of FGFR-4
mRNA was determined by quantitative RT-PCR with normalization to β-actin transcript levels.
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anti-V5 antibody followed byWestern blot with anti-Flag antibody (or
the converse) revealed direct interaction between both FGFR-4 variant
andHIP1, including an N-terminal truncated HIP1 (Figure 6A). Sim-
ilar results were seen in prostate cancer cell lines (LAPC4 and LNCaP;
data not shown). To map the domains of HIP1, which mediate the
interaction with FGFR-4, we made a series of HIP1 deletion con-
structs (Figure 6B) that were then expressed in bacteria and proteins
purified using streptavidin beads (Figure 6C ). We then incubated the
purified HIP1 proteins with lysates from 293T cells transfected with
V5-tagged overnight and immunoprecipitated with streptavidin
beads. The beads were washed, and Western blots were performed
using an anti-V5 antibody. As shown in Figure 6D, the region between
amino acids 601 and 798 containing the coiled-coil domain of HIP1 is
required for HIP1–FGFR-4 interaction.
HIP1 Potentiates the Biologic Activities of FGFR-4
We next examined the biologic affects of increased HIP1 expres-
sion. Cell lines expressing two- to fivefold higher levels of HIP1 were
established by stable transfection. In both PNT1A and DU145 pros-
tate cancer cells, increased expression of full-length HIP1 increases
proliferation in the medium containing FGF2 and insulin as the only
growth factors (Figure 7A). This effect was not seen with a truncated
receptor that lacks the lipid-binding domain of HIP1, which is re-
quired for its membrane localization in cells [29]. It should be noted
that DU145 cells are homozygous for the Gly388 allele, whereas
PNT1A cells are heterozygous Gly388/Arg388. The HIP1-overexpressing
PNT1A cells were then infected with a lentivirus expressing ShRNA
targeting HIP1 or FGFR-4. As can be seen in Figure 7B, knockdown
of FGFR-4 decreases growth of HIP1-overexpressing cells below that
of control PNT1A in defined medium with FGF2 and insulin as the
only growth factors. Thus, FGFR-4 is a major contributor to HIP1-
induced growth in response to FGFs in prostate epithelial cells. Similar
increases in proliferation in PNT1A cells expressing HIP1 were seen in
serum-containing medium that was significantly decreased by the
down-regulation of FGFR-4 with ShRNA (Figure 7B). These results
imply that, even in medium with serum, which contains a variety
of growth factors, FGFR-4 is a major effector of HIP1-mediated pro-
liferation. Similar increases in proliferation in HIP1-overexpressing
PNT1A cells were seen in the medium containing only 0.5% serum
(data not shown). PNT1A cells are immortalized but not fully trans-
formed and do not form colonies in soft agar. Expression of HIP1 leads
to colony formation in soft agar (Figure 7C ). Down-regulation of
FGFR-4 by 50% with ShRNA partially abolishes this phenotype
(HIP1 vs HIP1 ShR4, P = .03; Mann-Whitney), again implying that
FGFR-4 plays a role inmediatingHIP1 effects even in serum-containing
medium. It should be noted that down-regulation of HIP-1 by
ShRNA resulted in even more marked decreases in proliferation and
colony formation (Figure 7, B and C ), implying that other receptors
also contribute to the phenotype induced by HIP1 overexpression.
Discussion
We have shown previously in a large study of men with clinically
localized prostate cancer that heterozygosity of the FGFR-4 Arg388
was associated with increased risk of pelvic lymph node metastasis
at the time of radical prostatectomy and increased risk of biochemical
recurrence [15]. Heterozygosity of the FGFR-4 Arg388 has been as-
sociated with aggressive disease and clinical progression in a variety of
other malignancies [18–23]. Our prior in vitro studies have shown
that expression of the FGFR-4 Arg388 allele results in increased mo-
tility and invasion. Of note, recent studies by Sahadevan et al. [17]
have shown that knockdown of FGFR-4 in PC3 cells (homozygous
for Arg388) decreases proliferation and invasion in vitro. Thus, it is
clear that the FGFR-4 Arg388 allele can promote prostate cancer pro-
gression and is more effective than the Gly388 allele in this regard.
However, FGFR-4 Gly388 may also promote progression because
Sahadevan et al. [17] have shown that knockdown of FGFR-4 in
DU145, which are homozygous for the Gly388 allele, can decrease
proliferation and invasion of these cells in vitro. We have found that
DU145 cells express basal levels of HIP1 (data not shown), which
may be enhancing the biologic activity of the FGFR-4 Gly388 allele
in these cells.
Our current data indicate that the FGFR-4 Arg388 variant has in-
creased receptor stability and sustained phosphorylation, which prob-
ably explains its ability to promote prostate cancer initiation and
progression. Fibroblast growth factor receptor 4 associates with
HIP1, and the Gly388 variant is significantly stabilized by this inter-
action and results in phenotypes associated with cancer, including
increased proliferation in low growth factor conditions and colony
formation in soft agar. The decreased receptor degradation and sus-
tained phosphorylation after ligand stimulation that we observed
may substantially amplify receptor signaling by increasing surface
receptor concentrations and local FGF ligand (by decreasing degra-
dation) and by increasing the pool of early endosomes with bound
ligand, which can continue to transduce signals [29]. Further studies,
including direct comparison of the FGFR-4 Arg388 and Gly388 alleles
with other FGF receptors, are needed to understand the molecular
basis of the increased receptor stability and sustained phosphorylation
after ligand stimulation observed with the FGFR-4 Arg388 variant.
We have also demonstrated that the FGFR-4 Gly388 variant is sta-
bilized after ligand stimulation by the presence of HIP1. This may be
Figure 5. Stabilization of FGFR-4 Gly388 by HIP1. 293T cells were
transfected with V5-tagged FGFR-4 Arg388 or Gly388 with or with-
out HIP1, and cell surface receptors were labeled with biotin. Cells
were then stimulated with FGF2 and lysed at the indicated time.
Labeled receptors were then immunoprecipitated with streptavidin–
agarose, and FGFR-4 was detected by Western blot of the immuno-
precipitates with anti-V5 antibody.
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mediated through a direct interaction through the coiled-coil domain
located between amino acids 601 and 798. A recent study by Bradley
et al. [35] have shown a similar direct interaction between HIP1 and
EGF receptor, which requires a domain between amino acids 381
and 814 of HIP1. It has also been shown that amino acids 690 to
752 of HIP1 are required for the transformation by the HIP1/PDGR
beta fusion gene [36]. Thus, the domain we have identified overlaps
with the regions identified for direct interaction of HIP1 with EGF
receptors, although it is not clear that the interacting domains are
the same. HIP1 alters clathrin-mediated membrane trafficking of
EGF receptors [29,30], so it is likely that it also has a similar affect
on FGFR 4 Gly388, although other mechanisms are possible as well.
Figure 6. Direct interaction of FGFR-4 and HIP1. (A) 293T cells were transfected with Flag-tagged HIP1 or N-terminally truncated HIP1
(−183) with or without either FGFR-4 Arg388 or Gly388 (both V5-tagged). Vector control (Tag2B) is also shown. Cell lysates were then
analyzed by Western blot using anti-V5 or anti-Flag antibody or were used for reciprocal immunoprecipitation and Western blot analysis
with the two antibodies. (B) Map of HIP1 showing major domains and deletion fragments used to prepare bacterial fusion proteins. (C)
Purified HIP1 and HIP1 deletion bacterial fusion proteins on Coomassie blue–stained polyacrylamide gel after electrophoreisis. (D) 293T
cells were transfected with V5-tagged FGFR-4 and lysates prepared and incubated with purified HIP1 and HIP1 deletion constructs.
Complexes were then immunoprecipitated with streptavidin beads, and Western blot was performed with anti-V5 antibody. Control
is streptavidin beads but no purified protein.
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Interestingly, HIP1 did not further increase Arg388 stability, perhaps
because this variant is already extremely stable after ligand stimula-
tion. Further mechanistic studies are needed to determine the molec-
ular basis by which HIP1 stabilizes the FGFR 4 Gly388 but not the
Arg388 variant.
Rao et al. [30] have shown that HIP1 can strongly enhance EGF
receptor signaling, with potent biologic effects in NIH3T3 cells. We
have demonstrated that HIP1 has similar potent effects in prostate
and prostate cancer cell lines that are mediated in part through
FGFR-4, even in the culture medium containing serum, which is
a poor source of FGFs. Given the high local concentrations of
FGF2 in tumors in vivo [7] and the prevalent expression of other
FGFR-4 binding FGF ligands as autocrine factors [6,9–12], it is like-
ly that FGFR-4 plays an even more important role in mediating the
effects of HIP1 in human cancers in vivo. Other growth factor recep-
tors, including other FGF receptor family members as well as EGF
Figure 7. Biologic affects of HIP1 in prostate and prostate cancer cell lines. (A) Prostate (PNT1A) or prostate cancer (DU145) cell lines
expressing full-length HIP1, an amino terminal–truncated HIP1 (NT) or vector only were plated, and growth was determined in a defined
medium containing FGF2 and insulin as the only growth factors. Cell number was determined at 2-day intervals. Mean ± SD of tripli-
cates is shown. (B) PNT1A cells overexpressing HIP1 were infected with lentivirus expressing ShRNA targeting HIP1 or FGFR-4, and
stable expressors were selected and pooled. Quantitative RT-PCR showed 70% and 60% knockdown of HIP1 and FGFR-4 mRNA, re-
spectively (data not shown). Cells were then plated, and grown was determined in defined medium with FGF2 and insulin as the only
growth factors or serum-containing medium. Cell number was determined at 2-day intervals by cell counting. Mean ± SD of triplicates is
shown. (C) PNT1A cells as described in (B) were plated in soft agar. Colony formation was evaluated by counting. Mean ± SD of trip-
licates is shown.
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receptor family members, may well contribute to the biologic activ-
ities of HIP1 in prostate cancer. Rao et al. [30] noted that HIP1 in-
creases the level of FGFR-4 (and FGFR-3) protein in NIH3T3 cells
and hypothesized that these growth factor receptors may contribute
to the phenotype in HIP1-expressing NIH3T3 cells, although their
data indicated that EGF receptors probably played a dominant role
in these cells. Thus, the relative importance of different receptors in
mediating the phenotypes in cells expressing HIP1 may be cell type–
specific. Finally, it has been reported that HIP1 can act as an andro-
gen receptor coactivator [35], which may also promote prostate cancer
progression independent of its activities on growth factor receptors. It
should be noted that both PNT1A and DU145 cells do not express
androgen receptor, so the biologic effects we have observed are not
due to androgen receptor activation.
On the basis of the results reported here and by others, altered
FGFR-4 stability and/or trafficking is extremely common in prostate
cancer. Our prior studies have shown that more than half of all white
men with prostate cancer are hetero- or homozygous for the FGFR-4
Arg388 allele [15], and immunohistochemical studies have shown
that almost all prostate cancers express FGFR-4 [15–17]. Further-
more, approximately 50% of clinically localized prostate cancers ex-
press moderate to strong levels of HIP1 [31], and presumably the
expression of HIP1 is independent of the FGFR-4 genotype, al-
though there might be a selection for HIP1 expression in prostate
cancers homozygous for the Gly388 variant. If these two factors are
independent, it is likely that at least 75% of prostate cancers have
alterations of FGFR-4 signaling through receptor stabilization, and
on the basis of our studies and those of others, this altered signaling
has important biologic and clinical consequences. Thus, enhanced
FGFR-4 signaling is one of the most common alterations in human
prostate cancer. Fibroblast growth factor receptor 4 is therefore an
important therapeutic target in prostate cancer, and the development
of such therapies, as are being developed for other receptor tyrosine
kinases [37], should be pursued vigorously.
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